|
|
Kasumi-1
|
|
|
H Asou
|
|
Biosafety Level:
|
1
|
|
|
frozen
|
|
|
See Propagation
|
|
|
suspension
|
|
|
Homo sapiens (human)
|
|
|
myeloblast
|
|
|
Organ: peripheral blood
Disease: acute myeloblastic leukemia
Cell Type: myeloblast
|
|
|
In addition to the MTA mentioned above, other ATCC and/or regulatory permits may be required for the transfer of this ATCC material. Anyone purchasing ATCC material is ultimately responsible for obtaining the permits. Please click here for information regarding the specific requirements for shipment to your location.
|
|
|
|
|
Japan
Isolation date: November 8, 1989
|
|
|
Amelogenin: X
CSF1PO: 10,12
D13S317: 11,13
D16S539: 9,12
D5S818: 9,11
D7S820: 8,11
THO1: 6,9
TPOX: 8,9
vWA: 14
|
|
|
t(8:21) (q22;q22)
|
|
|
7 yrs juvenile
|
|
|
male
|
|
|
Japanese
|
|
|
ATCC complete growth medium: The base medium for this cell line is ATCC-formulated RPMI-1640 Medium, Catalog No. 30-2001. To make the complete growth medium, add the following components to the base medium: fetal bovine serum to a final concentration of 20%.
Atmosphere: air, 95%; carbon dioxide (CO2), 5%
Temperature: 37.0°C
|
|
|
Protocol: Cultures can be maintained by the addition of fresh medium or replacement of medium. Alternatively, cultures can be established by centrifugation with subsequent resuspension at 3 X 10(5) viable cells/ml.
Interval: Maintain cell density between 3 X 10(5) and 3 X 10(6) viable cells/ml.
Medium Renewal: Add fresh medium every 2 to 3 days (depending on cell density)
|
|
|
Freeze medium: Complete growth medium supplemented with 5% (v/v) DMSO
Storage temperature: liquid nitrogen vapor phase
|
|
|
40 to 48 hrs
|
|
|
Recommended medium (without the additional supplements or serum described under ATCC Medium):ATCC 30-2001
recommended serum:ATCC 30-2020
|
|
|
Differentiation Inducers: 12-O-tetradecanoylphorbol-13-acetate (TPA)
|
|
|
57589: Tashiro S, et al. Establishment of a human acute myeloid leukemia cell line (Kasumi-1) with 8;21 chromosome translocation. Blood 77: 2031-2036, 1991. PubMed: 2018839
61289: Miyoshi H, et al. The t(8;21) translocation in acute myeloid leukemia results in production of an AML1-MTG8 fusion transcript. EMBO J. 12: 2715-2721, 1993. PubMed: 8334990
61291: Miyoshi H, et al. t(8;21) breakpoints on chromosome 21 in acute myeloid leukemia are clustered within a limited region of a single gene, AML1. Proc. Natl. Acad. Sci. USA 88: 10431-10434, 1991. PubMed: 1720541
61292: Asou H, et al. 19-nor vitamin-D analogs: a new class of potent inhibitors of proliferation and inducers of differentiation of human myeloid leukemia cell lines. Blood 92: 2441-2449, 1998. PubMed: 9746784
61293: Kozu T, et al. Junctions of the AML1/MTG8(ETO) fusion are constant in t(8;21) acute myeloid leukemia detected by reverse transcription polymerase chain reaction. Blood 82: 1270-1276, 1993. PubMed: 8353289
61295: Pabst T, et al. AML1-ETO downregulates the granulocytic differentiation factor C/EBPalpha in t(8;21) myeloid leukemia. Nat. Med. 7: 444-451, 2001. PubMed: 11283671
|
